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The Bioelectricity Revolution:
A Discussion Among the Founding Associate Editors
Moderator: Dany Spencer Adams,1 Editor-in-Chief
Associate Editors, in order of appearance: Mustafa Djamgoz,2 Michael Levin,1 Min Zhao,3
Ann Rajnicek,4 Richard Nuccitelli,5 Annarosa Arcangeli,6 Richard Kramer,7 and Emily Bates8
Meet the Associate Editors
Dany Spencer Adams: Thank you all for joining me to
discuss Bioelectricity, the journal and the field. Let’s start
with introductions. Mustafa, would you like to begin?
Mustafa Djamgoz: Yes, of course. I am Mustafa Djamgoz,
Professor of Cancer Biology at Imperial College London.
Before that, I was a professor of neurobiology. I think it is my
rather unusual position in bioelectricity, having held two
professorships and sort of catalyzed the neuroscience and the
oncology fields through ion channels, to have opened more or
less a new field of investigation, the bioelectricity of cancer,
obviously, with all my colleagues, including, especially, Dr.
Mike Levin.
Being involved in the field of bioelectricity has been an
absolutely fascinating journey for me, seeing cancer cells
generate the kinds of electrical signals that one might only
expect to see in neurons and muscles, the so-called excitable
cells. I think the whole notion of excitability needs to be
defined. It is one of the things I would like to do in the
journal.
And, this has not only just been a nice journey, it has now
led to real clinical potential, so we are planning a first clinical
trial of metastatic disease focused upon an ion channel
blocker, which is very exciting.
DSA:Wow, congratulations. Thank you.Mike, would you
like to go next?
Michael Levin: Sure. I am Mike Levin. I am a Professor of
Biology at Tufts University, and my original background was
actually computer science. I was a software engineer inter-
ested in artificial intelligence and robotics. I fell in love with
developmental biology and embryos as a premier example of
how complex systems can self-assemble, self-repair, and
behave adaptively. It led me to study how living tissues store
and process information; it seemed to me that bioelectrical
signaling would be an ideal way for cells to communicate and
compute as they make decisions about what to build or re-
model.
Around ’97, ’98 or so, I started working on creating
functional molecular tools to probe long-range and local
bioelectric signaling in embryos, in particular at that time in
chick and frog embryos, as they tried to sort out which side
was left and which side was going to be right.
Since then we have been working on many aspects of
bioelectricity as it relates to everything from cancer, to em-
bryonic patterning, adult organ regeneration, synthetic bi-
ology, and so on.
DSA: Excellent. Thank you. Min, would you like to share
your experience?
Min Zhao: Hi. My name is Min Zhao, and I am currently a
Professor in the Department of Dermatology and Depart-
ment of Ophthalmology at the University of California
[UC], Davis.
I was trained as a trauma surgeon in China and went to
London to work with Geoff Burnstock on purinergic re-
ceptors. In ’94 I joined Colin McCaig and John Forrester to
start working on this fascinating question: how do wounds
use electric signaling to heal? That brought me into this
field.
I am still fascinated by this wonderful phenomenon, to
see that the tissue generates its own electricity, as Mustafa
just said, outside of the neurons and muscles, in the non-
excitable cells, like the epithelial cell, the fibroblasts, and
other types of cells, which we normally do not think of as
electrically active at the tissue level. So we are trying to
understand these things in the wound healing context and
trying to see whether we can develop therapeutic strategies.
We are still working on it.
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DSA: It is fascinating, isn’t it?
MZ: Yes. Very interesting, indeed.
DSA: Ann, can you tell us what captured your imagina-
tion and what you do?
Ann Rajnicek: Sure. I am Ann Rajnicek. I work at the Uni-
versity of Aberdeen in Scotland. And I have been interested in
bioelectricity ever since I started my PhD. I was doing my re-
search rotations, deciding what lab to work at at Purdue Uni-
versity, and I ended up working in the lab with Ken Robinson,
and I was absolutely smitten and enthused with the idea that this
simple electrical cue could be so important for so many things.
And I have since that time been working on issues related
to wound healing, wound repair, and tissue regeneration, with
particular interest and emphasis on central nervous system
regeneration, and more recently I’ve been looking into im-
mune cells and how immune cell function can be tweaked by
bioelectric signals.
I am excited to be part of this project, and I was absolutely
delighted when Dany approached me about being one of the
associate editors of the journal, because I think it is a really
exciting time for bioelectricity right now. There are so many
new things, and as you will hear from the people that are
talking with us today, there are lots and lots of different ideas
and potentials that we can explore.
DSA: I agree. Thanks, Ann. Richard Nuccitelli, could you
kindly introduce yourself?
Richard Nuccitelli: Sure, I am Rich Nuccitelli, currently the
Chief Science Officer at Pulse Biosciences. Our company is
commercializing the use of nanosecond pulsed electric fields
to treat tumors and skin lesions. I have worked in the field of
Bioelectricity my entire career, beginning with the invention
of the self-referencing vibrating probe with Lionel Jaffe. This
instrument has been used by dozens of investigators over the
past 30 years to detect the ionic currents flowing through
nearly all cells and embryos due to the polarized distribution
of ion channels and pumps. I was a professor at UC Davis for
23 years, where I studied the galvanotaxis of fibroblasts and
keratinocytes as well as the mechanism leading to the sperm-
induced calcium wave in the frog egg. Following that I was a
professor for 3 years at the Frank Reidy Research Center for
Bioelectrics at Old Dominion University, where I learned
about the amazing ability of nanosecond pulses to penetrate
into cells and tissues and trigger immunogenic cell death. My
wife and I then started BioElectroMed Corp, which has now
become Pulse Biosciences.
Bioelectricity is fundamental to all of life. Not only do we
generate all of our ATP [adenosine triphosphate] using the
electromotive force of hundreds of millivolts in mitochon-
dria, but also all of our senses rely on the flow of ionic cur-
rents. From the dark current in retinal rods to the mechanical
gating of channels in the hair cells in our ears, we see, hear,
taste, and smell with bioelectricity.
DSA: Annarosa Arcangeli, would you introduce yourself?
Annarosa Arcangeli: I am Annarosa Arcangeli, Professor of
General Pathology at the University of Florence. I have an
MD, with a specialization in Hematology and Oncology,
followed by a PhD in Experimental Oncology. I have been
studying cancer biology, and in particular cancer metabo-
lism, since the beginning of my scientific career, in the ’80s.
During my first studies I jumped suddenly in the bioelec-
tricity field, studying the role of ion fluxes in leukemia dif-
ferentiation. Afterward, thanks to a stage in Prof. Wanke’s
laboratory in Milan, I met the electrophysiology world, being
immediately fascinated by ion currents, which I studied in
excitable (neurons) and not excitable (erythroleukemia) cells.
I have worked with colleagues present around this table to
discover the unexpected role of ion channels in cancer cells,
and more recently, to define the conductive and not con-
ductive role of these fascinating membrane proteins.
I want to stress here that impressive achievements in the
treatment of cancer patients have been obtained in the last
twenty years. Nevertheless, cancer is still a devastating dis-
ease, let me say for both patients and her/his relatives.
Therefore, novel insights in the understanding of the biology
of cancer, including its electrical bases, focused to define
novel therapeutic strategies, are mandatory.
DSA: Absolutely. Thank you. Richard Kramer, would
you tell us about yourself next?
Richard Kramer: Sure. Yes. This is Rich Kramer. I am a
professor at UC Berkeley, Molecular Cell Biology Depart-
ment. I have worked for many years on various aspects of
electrophysiology in all kinds of cells, from ion channel
structure function to excitability to synaptic transmission,
mainly in the nervous system. But I have been interested in
other things as well.
Most recently, we have been developing and using tools to
impart light sensitivity on different kinds of ion channels and
receptors. This is a bit different than what might be called
‘‘conventional’’ optogenetics,which uses exogenous expression
of microbial opsins for photocontrol. Instead, we use synthetic
chemistry to plug photoisomerizable molecules onto endoge-
nous ion channels or receptors, and control these with light. We
call this optopharmacology, in contrast to optogenetics.
One of the places we are using this approach is in the eye,
where optopharmacology may be useful for restoring light
sensitivity in blinding diseases like retinitis pigmentosa, an
inherited disorder where rods and cones degenerate. We are
interested in the basic science of the retina, including un-
derstanding plasticity associated with photoreceptor loss as
well as the therapeutic development of these compounds as
potential treatments for blindness in humans.
DSA: I have used some of Richard’s chemicals, and it is
amazing what they can do. And finally, Emily.
Emily Bates: My name is Emily Bates, and I work at the
University of Colorado in the Anschutz Medical Campus.
I am in the Department of Pediatrics. I have been studying
bioelectricity since about 10 years ago, when I started my first
assistant professor position.
I study how ion channels impact developmental signaling.
I started with working on Kir2.1 and inwardly rectifying
potassium channels, and now I am kind of branching out and
doing screens in Drosophila for all different kinds of ion
channels that affect developmental signaling.
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Life as a Bioelectricity Researcher and an Editor
DSA: Thank you, everybody. I would like to go back to
Mustafa. You were the very first person who said ‘‘yes’’ to
being an associate editor on the journal, and I know you are
an incredibly busy person, and yet you were right there,
I think it was within hours of when I sent out the e-mails.
Why did you agree despite howmuch you have to do, and
what is your view of what our journal, Bioelectricity, will
become over the next couple of years and in the long term?
MD: Wow. That is a very, very good question. Before I an-
swer your question, which presses on a very sensitive nerve,
I just want to say, because a couple of colleagues had touched
on somewhat historic aspects, my interest in bioelectricity
started as a teenager, when I built a radio transmitter. And
I got electric shocks about 50 times a day while doing this.
And I was absolutely fascinated with what my body was
doing with this shock. And the rest is history. It became a
career. With that said, I do not advise that you go around
poking your fingers in electric sockets and things.
Dany, the answer to your question is this: in the ’90s, when
I became curious about the electricity of cancer cells, it was pure
curiosity. My father happened to die of cancer at a time when
people in Cyprus did not even know what cancer was. I started
questioning whether cancer cells generated electrical signals,
and more importantly, whether aggressive cancers differed in
their electrical signaling than normal cells and nonmetastatic
cells and so on. So we started the patch clamping, discovered
the voltage-gated sodium channel, and so on and so forth.
When I started then the business of publishing this work,
the response was incredible—as in, incredibly bad. The ion
channel people did not hesitate much, but the medical pro-
fession thought, you know, ‘‘This man is crazy. This is an
epiphenomenon. Ion channels belong to brain and central
nervous system and muscles and this and the other.’’
And then I put up a fight. And when I actually sat down and
said, ‘‘What am I going to do about this?’’ I was convinced
I was onto something. But the only way is to educate the field.
So I spent 6 to 7 years, through reviews and through
seminar presentations and conferences, convincing ulti-
mately the oncologists and the medical profession at large
that bioelectricity is important to medicine. And that is the
end I come from.
And when the journal idea came about, I mean, I had no
hesitation, because I saw the journal as serving amajor, major
role—if I may say so, for no less than humankind—in putting
forward something that Colin McCaig has done through his
reviews: Why is bioelectricity important? Why are bioelec-
trical signals important? And so on.
So this was just it. This was a formalization of what was a
timely and important development that had to be had in bi-
ology and medicine. I had no hesitation at all.
DSA: Who else has had that experience of trying to get
people to pay attention and finding that one group or more
than one group is really hesitant to think about it? Mike,
I know you have experienced it. Can you address that?
ML: Sure. One interesting thing I find is that different groups
have problems with different aspects of the work. I can al-
ways tell what kind of department I am giving a talk in based
on which part of the talk makes people scowl. For example,
certain things you can say to neuroscientists that they find
completely obvious, but the same thing in a molecular ge-
netics department is heresy. Bioengineers, cancer biologists,
regenerative medicine people, developmental biologists,
synthetic biologists, and cognitive science folks all have
different ideas of what’s obvious, surprising, or impossible.
And publication-wise, it becomes really interesting. I spe-
cifically remember the tail regeneration paper [Development,
2007] that Dany and I did together, on the role of channels
and pumps in tail regeneration in tadpoles.1 We found that
tadpoles used a vertebrate proton conductance to establish a
specific voltage state required for regeneration, but we could
shut it down and replace it with a completely heterologous
proton pump from yeast, with no structural or sequence ho-
mology, and everything worked as before, because the in-
structive physiological state was right.
One of the reviewers was a molecular biologist, and their
opinion was, ‘Ah, you have found this channel, which is the
gene for tail regeneration, so get rid of all this talk about
voltage and just talk about the gene for tail regeneration.’’
And of course, the other reviewer was a physiologist, and
they said, ‘‘Well, you have shown you can replace that
channel with a completely different pump and it still works, so
forget all the genetics, don’t focus on the channel, and just
leave all the physiology.’’ And the editor said, ‘‘Yes, very
good. Now do both of those things, and also make it shorter’’
‘‘So we had a heck of a time!
And this comes up again and again, because it is actually
quite difficult to find reviewers with appropriate expertise that
agree on anything. I think it is getting better now that the au-
dience and the community is growing. But trying to get re-
viewers who see the big picture beyond the individual silos has
definitely been a challenge. Still, I think it is absolutely getting
better. My hope for this journal is that it will serve as a beacon
for this field, where we will manage the review process to ad-
dress this problem and provide refereeing that is high-quality
andwell-informed in this field in order to drive the field forward.
DSA: I like your choice of words there: this journal will be a
beacon. Min, you have also been in the field a long time, and
you said you started in trauma surgery. That is an interesting
leap, and I wonder if you have a different perspective from
having been in medicine and now trying to convince physi-
cians that this is important. Can you add to this conversation?
MZ: Of course. I come from a different perspective. In
medicine, for the physician. the patients, they probably are
less worried about the mechanism or real science behind what
makes something work. If it works, it works. For example, if
you look at wound healing, if the wound heals, that’s the goal,
no matter what approach you took. If it heals, it’s good.
One of the critical things with respect to wound healing,
however, is to make the cells migrate into the wound or grow
into the wound, which is the healing process. If the cells do
not go there, then the wound does not heal.
When I was a graduate student in late 1980s, I had a long
conversation on healing of tissue damages with my super-
visor professor ZhengguoWang, a founding father of modern
trauma surgery in China. He happened to read something
about naturally occurring electric fields at wounds, and that
kept me super interested in this direction.
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I agree with what Mike just said. When you talk to dif-
ferent people about bioelectricity, the responses can be totally
different
I think this journal, Bioelectricity, is especially important.
The journal will introduce the field of bioelectricity to mul-
tiple audiences and get their attention and understanding of
what we are doing and what is happening in this field.
The Education of a Bioelectricity Researcher
DSA: I think that is a really important point and it is one of
ourmain goals: to keep this journal open andwelcoming and
educational—and to spread the word and grow the field.
Ann, I know you think a lot about not just bringing in
young scientists, but really bringing all scientists into this
field to understand the connections. Could you add your
perspective on that?
AR: Yes and yes. One of the things that will come out of
Bioelectricity, I think, and that is a strength of this whole
area—and it has been alluded to already—is how multidis-
ciplinary bioelectricity is. It requires skills and talents from
molecular biology and ion channel physiology and electro-
physiology and all kinds of things.
The problem is, when people review our papers, they
sometimes know something about one aspect of it, but they
do not understand all aspects of it. We need to develop a body
of people who understand how they knit together to form this
new field of bioelectricity. And I think that will be a strength
of Bioelectricity.
For example, when we think back to difficulties that we
have had in trying to get papers published, as Mike was al-
luding to earlier, my most memorable review of a grant once
by a referee was one sentence, and it said, ‘‘Does anyone
really believe this stuff anymore?’’ And that was it. And that
was the entirety of their feeling about the credibility of this
work. And of course, they are completely wrong.
DSA: Completely! This journal will put those doubts to rest.
AR:We will also show people how multidisciplinary we are:
we will take those aspects of the ‘‘proper’’ science that ev-
eryone believes in and put them together in a way that proves,
‘‘this is real stuff.’’
Another example: You take people who understand fully
the concept of a membrane potential, and there is no problem
with that, but then you introduce the concept of a trans-
epithelial potential, where you have a voltage difference
across a tightly sealed epithelium, and for some reason, this is
a huge leap of faith for them, and I have never quite under-
stood the difficulty in this concept.
But if you break it down and explain it to people and tell
them about the physiology behind it, suddenly you can almost
see a light switch on, and then they understand. Bioelectricity
will take people through the complexities of it piece by piece
and introduce people to how it fits together to make a much
bigger picture.
Our students are really good at this. We take students as
undergraduates—and I am involved in teaching on a variety
of topics, including neural development and regeneration and
physiology, cell biology—and you can introduce concepts
into individual courses.
By the time they come to their final year, you can put it
together for them in a way that makes a lot of sense. And
again, you can see the light switch on, and you can see how
enthused they are about it. And we have no trouble getting
students to volunteer to work in our labs on lab-based honors
projects, because they become really excited about it, as
excited as we are about it. I think that is the future, and
Bioelectricity will play an important role.
DSA: I am very pleased to hear that—very pleased. I want
to take this now to Emily. Can you tell us a little bit about
your educational experience? Could you tell us what ex-
actly caught you. When did the light go on for you?
EB: It was just in learning about the channelopathies,
and that these mutations occurred in ion channels. I had done
my whole undergraduate research training for 4 years in a
developmental biology lab as an undergraduate, and I had
taken upper-level developmental biology classes. I knew that
I had learned about all of the canonical developmental sig-
naling pathways, and none of them had mentioned ion
channels.
My plan was to work on neurological disease, so I learned
about ion channels and neuroscience as a PhD student. No
one mentioned the role of ion channels in development. So
there seemed to be two totally separate fields.
In my postdoctoral work in Louis Ptacek’s lab, I saw that
channelopathy patients had a syndrome of birth defects. Then
I learned about some of the other channelopathies, like
Timothy syndrome. The developmental symptoms were
similar among channelopathy syndromes. How ion channels
could affect development felt like a mystery to me.
When I started, it was hard to put the bioelectricity field
together, coming into it from just a mystery aspect. I just
started doing the science. As we learned more from our ex-
periments, it became more and more interesting to me, that
these ion channels could influence the canonical developmental
signaling pathways. It just seemed like the fields of develop-
ment and ion channel biology had been very separate.
I think the difficulty in following the field and bringing the
research together is one of the reasons we really need this
journal, Bioelectricity. We need to start having more con-
ferences that bring us together to allow us to have a bio-
electricity community to discuss our questions and our
findings. I agreed to be an associate editor because I feel like
the journal is one of the field’s biggest needs right now.
I would have loved to have this journal when I started! And
also, I agree with what Ann said—it is great to be able to talk
about this field with undergraduates and with graduate stu-
dents, and at conferences, as most of us do, I think, to spread
the word about this really exciting field.
DSA: I gather you put this together for yourself, and I
think that is the experience of many of us. Does anybody
else want to comment on that?
RK: Sure. I’ll chime in. I am a little bit of an outlier here in
that I have never called myself a bioelectricity researcher.
I have just studied electrophysiology and channels and
ROUNDTABLE DISCUSSION 5
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
A
BE
RD
EE
N
-Q
UE
EN
 M
OT
HE
R 
LI
B 
fro
m 
ww
w.
lie
be
rtp
ub
.co
m 
at 
11
/01
/18
. F
or 
pe
rso
na
l u
se 
on
ly.
 
electrical signaling, and sometimes they have been in neurons
and sometimes not.
I have been aware for my entire career about the role in
electrophysiology in development and regeneration, et cet-
era. So it is a little surprising, as someone who is a bit of an
outsider, to hear the resistance that you guys have encoun-
tered to this idea, because the importance of ion channels to
just about everything seems so obvious and just essential to
what I have learned throughout my education.
Tools for Bioelectricity
DSA: Richard N., I want to segue into talking about
medicine. One of themain topics that will be covered in the
journal is technology: tools for studying bioelectricity, and
how tools we use can be useful to physicians. And that is
what you work on.
Could you talk a little bit about your work and how you
think having a section devoted to technological advances
can contribute to the field and the journal?
RN: Certainly. Since the electric field is one of the funda-
mental forces of nature, it can be used as a tool to modify the
state of cells through signaling. The application of steady,
direct current electric fields has been shown to influence cell
migration and wound healing and pulsed electric fields can
penetrate into cells and organelles to directly influence many
different cellular functions, such as secretion, mitosis, and
programmed cell death. It is this latter application that is
particularly useful to oncologists faced with treating various
forms of cancer. We find that applying the appropriate
number of 200-ns-long pulses triggers immunogenic cell
death in every type of tumor studied. Not only does the tumor
self destruct, but it alerts the immune system of its presence to
generate cytotoxic T cells that search and destroy other tumor
cells. This is a nonthermal, drug-free therapy that only takes a
few minutes to trigger a cell death pathway that is integral to
all cells. Clearly there will be much interest in using bio-
electric tools such as this to treat various disease states.
DSA: The tools we publish will be very important, I agree.
Richard K., can tell us a little bit about your tool and how
it is different?
RK: Okay. There are tools—the sort of things that we have
made—which are chemical actuators or manipulators of ei-
ther channels, or receptors, or more generally, membrane
voltage. There is also a whole new generation of voltage
indicators, voltage-sensitive dyes, and genetically encoded
voltage sensors that are emerging. A close colleague of mine
at Berkeley, Evan Miller, is about to make a big splash with a
new voltage-sensitive dye, which, by the way, he is primarily
using on nonneural cells.
The venues for publishing basic cellular electrophysiology
have been changing over the years. The high impact neuro-
science journals, includingNeuron andNature Neuroscience,
have a very big task in covering the whole spectrum of re-
search in the nervous system. And the emergence of new
techniques has resulted in many more papers focused on
circuits, connectomics, on ‘‘big science’’ sorts of things, and
relatively less on cell or molecular physiology.
So, people have been scrambling to try to find good jour-
nals to publish good papers in these fields. So I think that
there is a big need for a fresh new venue that publishes papers
about new technology, new mechanisms, and new physio-
logical outcomes relevant for bioelectricity. It’s very com-
petitive and somewhat arbitrary what sort of studies make it
into the top tier journals, and there are potentially a lot of
people confused about where next to submit their otherwise
excellent paper. If Bioelectricity is known to be an inclusive
journal, which I would argue it is, it will really do well and
capture a lot of interesting papers frommany fields, including
advances in technology.
Bioelectricity in Medicine
DSA: Annarosa, you have been studying ion in channels in
cancer for many years now. In fact, we first met at an Ion
Channels in Cancer meeting you organized. Would you
tell us about the reception your ideas have received in the
medical community?
AA: One of the main problems I encountered during my
scientific life, was to convince people that the hERG1
channels could be considered good targets in oncology, de-
spite the fact that they are commonly identified as ‘‘unde-
sirable’’ targets. I think (and I have got good feedback from
the ‘‘pharma’’ world) that novel therapies, based on targeting
ion channels, including hERG1, will be considered for cancer
treatment in the near future.
DSA: Mustafa, you also work on cancer. In addition, you
have also been looking at side effects of things like anes-
thesia that affect ion channels.
I am curious as to how the medical community has
reacted to that, as well as the work you have done on ion
channels in cancer. For example, has that work been ac-
cepted? Are people excited to have a hypothesis about
these side effects? Is that something that people are lis-
tening to and welcoming?
MD: Indeed. I think we have not done justice to what you call
side effects. In fact, what we are talking about is the fact that
anesthesia and cancer, what I work on, are connected, obvi-
ously. But they are also connected through ion channels. So
you could actually—and there is evidence for it—affect
cancer progression through anesthesia, or medication like
painkillers, some of which also affect ion channels.
DSA: You bring up something else very important that
Bioelectricity will impact in important ways. That is that
there are many drugs that target ion channels and pumps
and are already approved for use in humans. Some of
them are even over the counter. I, and I am sure many of
you, have argued that this makes these ‘‘electrophar-
maceuticals’’ exciting candidates for use in the myriad
situations, like cancer, that we are discovering can be
treated by controlling ion flux. Bioelectricity will be the
leader in bringing these off-label uses to light.
Min, you also have something that is going into clinical
trials. Do you want to discuss how our journal could be
used to foster useful interaction between medicine and
bioelectricity researchers?
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MZ: I think having a ‘‘tools’’ section is key, and I know we
are going to include that section in the journal. For example,
Lionel Jaffe and RichardNuccitelli’s work on vibrating probes
[self-referencing ion-selective probes] has been, well, in this
field for over half a century. We do not really have newer ones
that have similar function. We are still using it. Bioelectricity
is where we will turn to find out new technology.
For the clinical part, I am not quite sure, because a lot of
people in clinical practice are using electric stimulation that are
not necessarily very scientific. The meaning attached to bio-
electricity. as Ann said before, people think, ‘‘Well, this is a
field and there are a lot of bad things attached to it. Why are
those people still working on it?’’ We must work to avoid that
kind of impression and get out of that mode of thinking. I will
be glad to see newer technologies introduced and will en-
courage scientists to submit that kind of research to the journal.
Frankenstein Was Not a Bioelectricity Researcher
AR: I absolutely agree. As we both will have experienced in
the past, and many of us will have experienced, people still
see. in their heads they conjure up an image of Frankenstein.
MZ: Yes.
AR: And we are not doing Frankenstein science.
DSA: A quick side note: In Shelley’s original story, Fran-
kenstein was not doing science at all. Behind the backs of
the scientists who are his graduate advisors, he is practic-
ing alchemy. That is certainly not what bioelectricity is.
AR: Absolutely! There is real, genuine physiology and bio-
physics behind what we do, and we will educate people to the
understanding that there is real science here. We are not
doing galvanic reanimation here. That is not what we are
about. We are about real science.
I think we have all found that as we have published papers
and put in our grant applications, we have had to be a little bit
more careful and had to have extra work, and maybe a
mechanism that would not have been necessary for the first
publication of a phenomenology in a different subject area.
So I think we have often felt that we have had extra rigor
demanded of us by the refereeing community. And so we
have evolved into a community of scientists that are very
careful, and I think we should be very proud of that, and that
will come through in our journal.
DSA: That is an interesting observation, and I had not
thought of it that way. But you are right. There is a level of
care and robustness in our results that is something we
should be proud of and we should highlight.
Bioelectricity and Bioelectricity
DSA: We’ve been talking about some specific categories
of research we will publish: basic research, medicine, cre-
ating new tools. Let’s zoom back out again and talk a little
about the big picture. What is your vision for the journal?
RK: One question in terms of the journal is, how broadly are
we defining bioelectricity? Of course, we have a community
of people that already want to publish here. Do you see it
growing to include a wider range of the role that electrical
signaling plays in excitable and nonexcitable cells? Cancer,
immune responses, endocrine and exocrine function—there
are an endless range of interesting processes involving or
influenced by electrical events.
What are we going to use as our definition of bioelectricity?
DSA: That is a great question. I am just going to jump in
here. At the beginning, I thought, ‘‘Well, this is going to be
anything that does not go to a neuroscience journal or a
biophysics journal.’’ So, nonexcitable cells—although I
agree that excitable versus nonexcitable is maybe a spe-
cious distinction. But of course it cannot be defined by
what it is not.
MD: I think that it is the fundamental question which I pre-
sume, Dany, you will tackle in your first editorial.
DSA: Yes. And probably in many editorials over the years.
From the very beginning, though, this group of people that
is on this phone call right now—you, the associate editors—
will work together to make sure this field has a strong
central foundation on which to build. Richard, in answer to
your question, we will publish subject overviews, perspec-
tives, and book reviews. That will include work done by the
pioneers talking here today, including work on develop-
ment, regeneration, cancer, tools, medical advances, wound
healing, etc. Alongside that, we will publish the best work
from the ‘‘endless range of interesting processes,’’ such as
work on bioelectricity in microbiology, botany, immunity,
etc. We need to tend to the field as it grows while letting it
grow according to the curiosity of all interested scientists.
EB: I also think we should err on the side of inclusion, be-
cause we want the field to grow, and people can learn more
about it by becoming familiar with the journal. I have learned
a lot from the neuroscience community and also from the
development community.
While I want there to be a journal where we have a col-
lection of reviewers and editors that understand the aspects of
ion channels and the aspects of development and regenera-
tion, it is also important that we include more people from
other disciplines who start thinking of themselves as asso-
ciated with the field of bioelectricity.
RN: My feeling is that Bioelectricity should include any re-
search into the interaction with or use of electricity by living
things. This would be the broadest definition of our focus but
one that will serve to illustrate the relevance of this field to
everything that we do.
MZ: I agree with what all has been just said, I also want to see
this field as inclusive.
DSA: I agree completely. Mike, like others here, you have
done a lot of work as an ambassador for the field. Can you
comment on inclusion and distinction?
ML: I think what Emily said is right on. And this ties into a
question that I hear all the time, which is, ‘‘Howmany people
are actually in this field?’’ People say, ‘‘Well, I have never
heard of bioelectricity. How big is the field?’’ And I think if
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you define it as the people who explicitly call themselves
workers in bioelectricity, then it is quite small—very small.
But on the other hand, I think nowadays especially there
are lots of people that work in bioelectricity that do not neces-
sarily know they work in bioelectricity. For example, there are
lots of people who work on various channelopathies from a
genetics angle: They eventually clone the gene and find that now
they have to think about how ion channels regulate patterning.
I sometimes see these channelopathy papers for example,
and I will e-mail the authors, and say, ‘‘Hey, did you know all
this other stuff existed?’’ And they say, ‘‘Oh, my God, in-
credible. We have never heard of any of this, but it sure helps
us understand what’s going on.’’ Same with bioengineers
who apply electric fields not knowing about the endogenous
roles, cancer biologists who pull out ion channels as onco-
genes, or neuroscientists who don’t think about the fact that
many cells can actually do what neurons do (just slower), and
had been doing it for a long time before brains came on the
scene. Also, for example all the people in synthetic biology
that are making interesting new materials that are absolutely
relevant for us, all of these people may or may not know they
are in the field, but I think they are in the field.
And I agree with Emily that I think our goal is to bring
them into the fold and help forge the connections, because
I think that is one of the most interesting aspects of this field:
it is not just another set of biophysical mechanisms that de-
velopmental biologists now have to worry about, but rather,
there are some amazing conceptual aspects of bioelectricity
that may link this work to all kinds of areas in synthetic
biology and origin of multicellularity and primitive cognition
and even aspects of things like unconventional computation.
And so I think we should absolutely err on the side of
pulling everybody in, and then seeing what the center of
gravity ends up looking like and where the borders of this
discipline might turn out to be.
EB: I would just like to say that is exactly how I was brought
in. Mike mentioned e-mailing people that publish on channe-
lopathies. Mike sent an e-mail and sent me a few papers, and
that is how I met him and then, through him, I met Dany and
others. So I amgrateful toMike that he reaches out like he does.
AR: I just want to say I agree with what Emily and Mike and
you as well, Dany, have said. We should be inclusive, be-
cause we do not have a crystal ball. We cannot predict what
technologies and techniques might emerge in the future. So
we need to keep an open mind about this. As much as we
would expect other people to have open minds for us, we
should have one for ourselves, as well.
So I think one of the things that Mike mentioned in par-
ticular was this thinking about bioengineering and new ma-
terials and new techniques. We cannot see into the future and
know for sure what or how this work that we are doing that
relates to developmental biology might end up leading to a
clinical situation that could be aided using bioelectrical
phenomena. And that is the sort of thing that Mustafa was
mentioning in the introduction.
I think the whole thing can go full circle—what we do in
the petri dish, what we learned from embryos—and then
transferring that into the clinic. And new materials, new en-
gineering possibilities are just emerging every day. We
should just keep an open mind about it.
DSA: Richard, are we answering your question?
RK: Yes. For example, someone working on synapse de-
velopment, that is clearly neuroscience, but it is part of de-
velopment and there have been suggestions about electrical
fields driving receptors to aggregate electrophoretically.
There is a lot of overlap, I think.
And I guess I would be hesitant to define this field by
‘‘what it is not’’—you know, saying it does not necessarily
include the nervous system or conventional synapses.
DSA: Correct, we cannot say ‘‘these are the boundaries,’’
at this point, because, as you all have been saying, you
cannot predict who is going to come up with the next
imaginative, wonderful combination that will appear on our
doorstep, and we should be able to say, ‘‘ Yes, let’s include
this.’’ What we can do is say, ‘‘This is the field, so far.’’
RK: Right.
This is what Ann was saying earlier. Bioelectricity, by
definition, is multidisciplinary. We are all coming at many
questions from different angles. In short, there is a lot to
cover, and we have a lot to do. But this journal is an exciting
development, and I think that we all share in the excitement.
DSA: We are at a very exciting moment indeed.
Bioelectricity will provide a focal point for a dynamic
field, a task that will require many skills. Our editorial
decisions will inevitably influence who decides to calls
themself a bioelectricity researcher. I take that respon-
sibility very seriously, and I know you do as well.
Last Words
DSA: We’ve talked about the role of the journal as an
anchoring point for an inclusive and diverse field, and the
importance of having a cadre of people who can review
these kinds of papers. We’ve also discussed how our own
experiences have informed our view of the journal’s role
in discovery and in education, and how the journal will
spread the word to the scientific community in general.
Finally, I very much appreciate your thoughts and in-
sights into the importance of being inclusive and open to
different research questions, novel ideas, and inventive
tools for research and medicine.
Would anybody like to add some final thoughts?
RN: Bioelectricity encompasses all of life, and life would not
exist without it. That this fact is not common knowledge
serves as a challenge to all of us. We must not only publish
the most exciting new findings, but wemust publicize them to
the nonscientists out there so that everyone can appreciate the
marvels of bioelectricity.
ML: Bioelectricity is an incredibly exciting emerging field:
it’s a perfect example of an interdisciplinary undertaking that
spans from basic science (evolutionary developmental bi-
ology) to biomedicine (regeneration, cancer, and birth de-
fects). It is an ideal place for energetic young scientists to
look for the next open vistas of discovery for their careers.
We need to make this journal a central touchstone for existing
workers and bioelectricity researchers-to-be—the place to go
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to see the latest discoveries, and the place to send their work
for the best review experience.
AA: We all are convinced that bioelectricity is an emerging
field, spanning from basic science to medicine. Our main job,
through our journal, will be to join bioelectricity researchers
to the whole scientific community, to broaden this relevant
scientific field.
MD: I just want to say, finally, as possibly the oldest person
around the table, that in my experience of having done var-
ious editorial things that the single most important factor to
sell the journal is the editor, editor, and editor.
So I think, Dany, that is obviously you, but you have got
the associate editors. I think you should use the associates
very well, and altogether, to make a success of what joins us
together today, and that is the success of the journal and the
field at large.
DSA: That’s another important point. As we’ve been
discussing, the field is multidisciplinary and has insights
and tools to offer to a wide range of other fields as well as
other scientists and everyone else. We are all invested in
the success of this endeavor. And thank goodness, because
no one could do this alone. So, I will take your comment,
Mustafa, as an offer and point out that it is an honor to be
part of this team. To say I have faith in you all is ridicu-
lous—zero faith is necessary. There is somuch evidence of
the excellence and enthusiasm of each of you, and it is
clear from this roundtable that, as a team, we will reach
our goals for this journal and this new field.
Thank you all very much for your time today and in the
future.
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